Botulinum Toxin for Treatment of Jaw Opening Dystonia in Hallervorden-Spatz Syndrome

2001 ◽  
Vol 45 (4) ◽  
pp. 287-288 ◽  
Author(s):  
D. Dressler ◽  
M. Wittstock ◽  
R. Benecke
Keyword(s):  
Botulinum Toxin ◽  
Jaw Opening

Reduced jaw opening from paradoxical activity of mandibular elevator muscles treated with botulinum toxin

2003 ◽  
Vol 10 (6) ◽  
pp. 695-699 ◽  
Author(s):  
M. Bakke ◽  
L. M. Werdelin ◽  
T. Dalager ◽  
A. Fuglsang-Frederiksen ◽  
S. Prytz ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Jaw Opening

scholarly journals Jaw-Opening Dystonia: Quality of Life after Botulinum Toxin Injections

2011 ◽  
Vol 90 (2) ◽  
pp. E9-E12 ◽  
Author(s):  
Steven J. Charous ◽  
Cynthia L. Cornelia ◽  
Wenqing Fan
Keyword(s):  
Quality Of Life ◽  
Botulinum Toxin ◽  
Jaw Opening ◽  
Botulinum Toxin Injections

scholarly journals Jaw-opening oromandibular dystonia secondary to Wilson's Disease treated with botulinum toxin type A

2012 ◽  
Vol 70 (6) ◽  
pp. 407-409 ◽  
Author(s):  
Hélio A.G. Teive ◽  
Leandro E. Klüppel ◽  
Renato P. Munhoz ◽  
Nílson Becker ◽  
Paulo R. Müller ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Wilson’S Disease ◽  
Botulinum Toxin Type A ◽  
Case Series ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Wilson's Disease ◽  
Common Side Effect ◽  
Oromandibular Dystonia ◽  
Jaw Opening

We have reported a case series of five patients with jaw-opening oromandibular dystonia secondary to Wilson's disease (WD), in which the patients were treated with botulinum toxin type A (BTX-A). In all cases, dystonia score was partially reduced three weeks after injections. The most common side effect was transient mild dysphagia. This preliminary study showed that jaw-opening oromandibular dystonia in WD may be partially responsive to the use of BTX-A.

scholarly journals Oromandibular dystonia: a case report of the lateral pterygoid muscle involvement and treatment with botulinum toxin A

2016 ◽  
Vol 6 (3) ◽  
Author(s):  
Athanasia Alexoudi ◽  
Zoi Dalivigka ◽  
Anna Siatouni ◽  
Anastasia Verentzioti ◽  
Stylianos Gatzonis
Keyword(s):  
Case Report ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Individualized Therapy ◽  
Oromandibular Dystonia ◽  
Muscle Involvement ◽  
Jaw Opening ◽  
Jaw Protrusion ◽  
Severe Difficulty ◽  
Botulinum Toxin Treatment

The objective of the present case report is to punctuate the importance of individualized therapy procedures and the accurate diagnosis of the muscles involved in oromandibular dystonia and underline the role of electromyography (EMG). We report a woman who presented sustained jaw movement towards the left, severe difficulty in jaw opening and jaw protrusion. The patient was treated with injections of botulinum A toxin in lateral pterygoid, masseter, platysma, sternoclidomastoid, temporalis muscles with EMG guidance. She experienced an 80% reduction of her symptoms after the first injection. In jaw deviation dystonia symptoms impressively respond to botulinum toxin treatment of the pterygoid muscle. Individualized therapy procedures are necessitated.

Severe Drooling and Treatment With Botulinum Toxin

2012 ◽  
Vol 21 (1) ◽  
pp. 15-21
Author(s):  
Merete Bakke ◽  
Allan Bardow ◽  
Eigild Møller
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Health Risk ◽  
Flow Rate ◽  
Clinical Evidence ◽  
Acetylcholine Release ◽  
Psychosocial Problems ◽  
Rate Reduction ◽  
Local Inhibition ◽  
Surgical Treatments

Severe drooling is associated with discomfort and psychosocial problems and may constitute a health risk. A variety of different surgical and non-surgical treatments have been used to diminish drooling, some of them with little or uncertain effect and others more effective but irreversible or with side effects. Based on clinical evidence, injection with botulinum toxin (BTX) into the parotid and submandibular glands is a useful treatment option, because it is local, reversible, and with few side effects, although it has to be repeated. The mechanism of BTX is a local inhibition of acetylcholine release, which diminishes receptor-coupled secretion and results in a flow rate reduction of 25–50% for 2–7 months.

Sign in / Sign up

Export Citation Format

Share Document